Critics slate ethical leeway in California stem-cell proposal
By Jonathan Knight,
Nature
| 09. 16. 2004
Opponents of California's $3-billion plan to fund embryonic
stem-cell research say that the proposal would give researchers carte
blanche to rewrite well-established ethical guidelines to suit their
needs.
They say the research institute planned
under the initiative will be exempt from legislative supervision and,
if established, will be able to make its own rules about conflicts of
interest and informed consent.
Proponents are
reacting angrily to the charges, saying that the proposal provides the
highest possible level of accountability and will serve as a model of
how science can be funded at the state level.
The
California Stem Cell Research and Cures Initiative will appear as
Proposition 71 on the ballot in the elections due on 2 November. If
passed, it will authorize a bond issue of nearly $3 billion over ten
years to fund embryonic stem-cell research and infrastructure. It will
create the California Institute for Regenerative Medicine to distribute
the funds.
But public opinion is sharply divided on
the proposition, with 45% in favour and 42% opposed. A California
columnist has branded it an "audacious raid on the...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...